NX1 Nexalis Therapeutics Limited
Healthcare · Biotechnology
· website
$0.01
52wk 0.01 – 0.04
Overall
—
Value
—
Growth
—
Health
—
Quality
—
Momentum
—
Dividend
—
Price
About Nexalis Therapeutics Limited
Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. The company develops IRX-211 for the management of breakthrough cancer pain and IRX-616a for the treatment of panic disorder, which are inhaled medications delivered through a pressurized metered dose inhaler. It also develops SRX-25 for treatment resistant depression. The company was formerly known as InhaleRx Limited and changed its name to Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is based in Melbourne, Australia.
Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$2.78M
P/E (trailing)
—
P/E (forward)
—
EPS (trailing)
-0.01
Dividend yield
—
Payout ratio
0.0%
Beta
0.18
EV / EBITDA
—
Price / Book
-2.75
ROE
—
Operating margin
-160.4%
Net margin
-164.1%
Total cash
$436,900
Total debt
$741,278
Current ratio
0.69
Debt / Equity
—
Free cash flow
$-334,854
Avg volume
183,825
Latest annual results
(FY ending 31 Dec 2025)
- Revenue—
- Gross profit—
- Operating income-$2.47M
- Net income-$1.62M
- Diluted EPS-0.01
- Free cash flow-$888.17K
- Net debt$304.38K